/

PCRX

Pacira BioSciences, Inc.Pre-market

36.35+0.04 +0.11%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delayPre-market 36.35 0.00%

Open

36.32

Prev close

36.31

Day range

36.3236.35

52-week range

18.8036.46

Volume

2.01M1.79×

Mkt cap

1.45B

P/E ttm

103.86

Fwd P/E

10.51

EPS ttm

0.3500

Div yield

0.00%

Earnings

Aug 4, 2026

From 52w high

−0.30%

Price Chart

Yahoo Finance · delayed

PCRXOct 12, 2026O 36.34H 36.35L 36.32C 36.35+0.04 (+0.11%)Vol 2.01M

SMA 5025.76
SMA 20024.03

1Y change +62.64% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

PCRX Pacira BioSciences, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +45.11%
1 month: +43.34%
3 months: +42.33%
6 months: +51.08%
Year to date: +40.46%
1 year: +62.64%

Valuation & ownership

Market cap: 1.45B
Enterprise value: 1.61B
P/E (ttm): 103.86
Forward P/E: 10.51
PEG ratio: 0.98
Price / book: 2.15
Price / sales (ttm): 1.94
EV / EBITDA: 12.99
EPS (ttm): 0.3500
EPS (forward): 3.46
Beta (5y monthly): 0.25
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 39.91M
Float: 36.19M
Short % of float: 29.12%
Short ratio (days): 14.52
Held by insiders: 1.74%
Held by institutions: 112.99%
Avg volume (3m): 1.12M
50-day average: 25.76
200-day average: 24.03
52-week change: +62.64%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): overbought 84.7
vs 50-day SMA: +41.09%
vs 200-day SMA: +51.24%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.75%
Realised vol (20d, ann.): 133.2%
From 52-week high: −0.30%
From 52-week low: +93.35%

ANR

Analyst Consensus

7 analysts

Consensus

Hold

2.78 on a 1 (strong buy) – 5 (sell) scale

Mean target

33.57

−7.64% implied

Low 25.00Median 36.50High 36.50

Recommendation trend

Now1 / 8 / 0
1m ago / 3 /

DES

About Pacira BioSciences, Inc.

Yahoo Finance profile

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 825
Headquarters: Brisbane, CA, United States
Website: pacira.com
Officers: Mr. Frank D. Lee CEO & Director
Mr. Shawn M. Cross

SEAS

Seasonality · PCRX

2011–2026 · monthly returns

Strongest month Jan +6.79%Weakest month Jul −3.19%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-20.6	6.7	3.1	12.8	-8.9	9.3	4.1	-1.9	-3.3	45.1			+40.5%
2025	39.8	-8.7	3.3	8.2	-3.9	-7.5	-11.8	26.5	-3.4	-17.0	10.2	9.8	+37.4%
2024	-3.4	-8.8	-1.7	-10.2	15.5	-5.7	-27.8	-24.6	-3.3	10.3	1.9	11.4	−44.2%
2023	1.7	8.4	-4.1	11.0	-16.1	5.4	-9.3	-2.9	-13.1	-7.9	-3.5	23.7	−12.6%
2022	4.3	6.2	14.4	-2.3	-15.2	-7.8	-3.0	-7.2	1.4	-2.7	-6.8	-20.0	−35.8%
2021	10.4	11.2	-4.6	-9.9	-4.0	0.0	-2.9	0.6	-5.5	-6.6	0.7	14.3	+0.6%
2020	-4.6	0.4	-22.7	23.1	6.4	19.4	0.3	18.8	-3.8	-13.0	15.9	-1.2	+32.1%
2019	-5.4	1.2	-7.6	4.6	9.3	-0.0	0.9	-15.2	2.2	6.4	14.2	-2.0	+5.3%
2018	-20.3	-14.0	-0.5	6.3	3.5	-6.4	25.4	17.3	4.2	-0.5	-1.1	-11.0	−5.8%
2017	19.0	13.7	4.3	6.5	-8.5	7.4	-17.2	-3.5	-1.4	-14.6	44.1	-1.2	+41.3%
2016	-22.6	-12.5	1.9	2.1	-14.0	-27.5	7.5	9.3	-13.7	-7.1	0.2	1.4	−57.9%
2015	21.1	6.9	-22.6	-22.9	14.2	-9.6	-6.1	-13.4	-28.6	21.5	29.6	18.6	−13.4%
2014	19.2	14.2	-10.5	-2.1	13.3	18.4	0.2	17.7	-10.5	-4.2	1.2	-5.6	+54.2%
2013	10.9	12.8	32.0	0.0	1.5	-1.0	17.0	6.7	32.7	5.1	9.3	4.2	+229.1%
2012	24.9	-0.9	7.9	-2.9	-5.3	51.0	-4.6	18.6	-4.2	-9.6	8.4	2.5	+102.0%
2011			2.9	48.5	35.7	-16.1	-16.5	-23.6	29.6	-1.5	-25.2	18.2	+25.4%

INSD

Insider Activity · PCRX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

69.8K shares

Sells, 6 months

44.4K shares

Net shares

+25.4K

Net change in insider shares

+3.80%

Date	Insider	Transaction	Shares	Value
Aug 16, 2026	Slonin JonathanOfficer	Sale at price 23.23 per share.	3K	$70.62K
Jun 10, 2026	Riker Lauren BullaroOfficer	Sale at price 23.50 per share.	6.1K	$143.70K
Jun 9, 2026	Brege Laura ADirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 9, 2026	Yang Michael J.Director	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 9, 2026	Froimson MarkDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 9, 2026	Hirawat SamitDirector	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 9, 2026	Christie Christopher J.Director	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 9, 2026	Young Alethia R.Director	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 9, 2026	Bigal Marcelo M.D., Ph.D.Director	Stock Award(Grant) at price 0.00 per share.	6.4K	—
Jun 3, 2026	Williams Kristen MarieOfficer	Sale at price 22.27 per share.	10.3K	$228.47K
Apr 22, 2026	Cross Shawn M.Chief Financial Officer	Sale at price 25.16 per share.	12.9K	$325.60K
Apr 22, 2026	Cross Shawn M.Chief Financial Officer	Conversion of Exercise of derivative security at price 16.45 per share.	12.9K	$212.88K
Apr 21, 2026	Cross Shawn M.Chief Financial Officer	Sale at price 25.01 - 25.14 per share.	12.1K	$302.60K
Apr 21, 2026	Cross Shawn M.Chief Financial Officer	Conversion of Exercise of derivative security at price 16.45 per share.	12.1K	$198.37K
Mar 16, 2026	Froimson MarkDirector	Sale at price 21.81 per share.	500	$10.90K
Mar 16, 2026	Slonin JonathanOfficer	Sale at price 22.82 per share.	3.3K	$74.42K
Feb 10, 2026	Riker Lauren BullaroOfficer	Stock Award(Grant) at price 0.00 per share.	19.3K	—
Feb 10, 2026	Williams Kristen MarieOfficer	Stock Award(Grant) at price 0.00 per share.	54.5K	—
Feb 10, 2026	Cross Shawn M.Chief Financial Officer	Stock Award(Grant) at price 0.00 per share.	49.1K	—
Feb 10, 2026	Lee Frank DonChief Executive Officer	Stock Award(Grant) at price 0.00 per share.	261.8K	—

13F

Investors Holding PCRX

latest 13F filings of 29 followed managers

Investors holding PCRX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$44.0M	0.06%	1.73M	−5.0%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

PCRX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

PCRX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pacira BioSciences, Inc.

Seasonality · PCRX

Insider Activity · PCRX

Congress Trades · PCRX

Investors Holding PCRX

Investors Holding PCRX

Congress Trades · PCRX

Insider Activity · PCRX

Seasonality · PCRX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pacira BioSciences, Inc.

Financial Snapshot

Earnings & Dividends

News